New Technologies to Assess Food and Cosmetic Safety

New Technologies to Assess Food and Cosmetic SafetyCFSAN scientists are developing/using medium throughput biomarker assays and integrated alternative model systems to assess the safety of food and cosmetic components. It is our hope that the identification of medium throughput screening methods and alternative models will improve toxicity characterization, increase efficiency, reduce cost as well as refine, reduce or replace animal use.

ON TRACK

A. Foods:

9/30/2015

On Track

sub

i. Evaluate liquid chromatography quadripole mass spectrometer (LC/MS/MS)-based global metabolomics in cultured human hepatocyte cell lines and cultured primary human hepatocytes as a method for discovery of biomarkers of liver toxicity

9/30/2012

(9/30/2013)

On Track

sub

ii. Evaluate the effects of gender on hepatotoxicity using male- and female-derived liver cells in vitro. This includes evaluating the effect of gender specific hormones, their precursors and metabolites on potential liver toxicants on human liver cells

3/31/2013

On Track

sub

iii Evaluate the interaction of inflammation including inflammatory cytokines (large molecules that signal changes in the animal's internal environment which creates a hostile environment for an invading organism) and liver toxicants using liver cells in vitro

9/30/2013

Not Yet Started

sub

iv. Present data collected from these studies at scientific meetings and in scientific publications

9/30/2015

Not Yet Started

B. Cosmetics

9/30/2015

On Track

sub

i. Initiate percutaneous absorption (skin absorption) studies of nanomaterials (dendrimers) with surface modifications with and without radiolabel using diffusion cell techniques. Studies will be conducted using pig and human skin. The ability of the nanomaterial to penetrate the skin will be determined visually using laser confocal microscopy and quantitatively using liquid scintillation counting (a method used to determine how much of the material has penetrated into the skin).

5/28/2011

(5/28/2013)

On Track

sub

ii. Continue percutaneous absorption studies and analysis of dendrimers including repeat dose studies and enhanced absorption studies of model compounds

10/31/2011

(10/31/2013)

On Track

sub

iii. Continue analysis of diffusion cell studies of dendrimers, repeat dose studies and model compounds

4/30/2012

(4/30/2014)

Not Yet Started

sub

iv. Complete analysis of diffusion cell studies of dendrimers, repeat dose studies and model compounds

6/30/2013

Not Yet Started

sub

v. Present data collected from these studies at scientific meetings and in scientific publications

9/30/2015

Not Yet Started

http://www.fda.gov/AboutFDA/Transparency/track/ucm206221.htmFDA-TRACK CFSAN Dashboard